Stay updated on Safety, PK, and PD of FDL169 in CF - Clinical Trial
Sign up to get notified when there's something new on the Safety, PK, and PD of FDL169 in CF - Clinical Trial page.

Latest updates to the Safety, PK, and PD of FDL169 in CF - Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference4%
- Check20 days agoChange DetectedAdded version label v3.1.0 and removed multiple drug-safety topics (drug safety, counterfeit drugs, pharmaceutical preparations, substandard drugs) along with an older revision reference (v3.0.2); content now omits several core safety sections. If these topics were critical, this is a notable reduction in coverage.SummaryDifference0.5%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; the old revision label was removed. The 'Back to Top' element was also removed, which is a minor UI change.SummaryDifference0.3%
- Check41 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.3%
- Check48 days agoChange DetectedThe web page has been updated to include a new facility name and location in Prague, Czechia, along with significant additions related to drug safety and cystic fibrosis treatments, while removing some redundant location terms and previous mentions of cystic fibrosis.SummaryDifference4%
- Check63 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Safety, PK, and PD of FDL169 in CF - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety, PK, and PD of FDL169 in CF - Clinical Trial page.